Omnicell (NASDAQ:OMCL) Lowered to “Hold” Rating by Zacks Research

Omnicell (NASDAQ:OMCL) was downgraded by investment analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued on Tuesday,Zacks.com reports.

OMCL has been the topic of a number of other research reports. KeyCorp increased their price target on shares of Omnicell from $60.00 to $70.00 and gave the company an “overweight” rating in a report on Tuesday, April 28th. Wells Fargo & Company upped their price objective on Omnicell from $52.00 to $55.00 and gave the company an “overweight” rating in a research report on Thursday, April 23rd. Wall Street Zen upgraded Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 10th. Weiss Ratings raised Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a report on Thursday, May 7th. Finally, Craig Hallum restated a “buy” rating and issued a $55.00 price target on shares of Omnicell in a research note on Wednesday, April 29th. Seven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, Omnicell currently has an average rating of “Moderate Buy” and a consensus target price of $59.86.

Omnicell Price Performance

Shares of NASDAQ:OMCL opened at $45.12 on Tuesday. Omnicell has a 1-year low of $26.84 and a 1-year high of $55.00. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.50 and a quick ratio of 1.29. The business has a fifty day moving average price of $42.20 and a 200-day moving average price of $41.50. The company has a market capitalization of $2.05 billion, a PE ratio of 102.55, a PEG ratio of 1.15 and a beta of 0.96.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Tuesday, April 28th. The company reported $0.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.33 by $0.22. Omnicell had a net margin of 1.67% and a return on equity of 4.00%. The company had revenue of $309.88 million for the quarter, compared to analysts’ expectations of $304.02 million. During the same quarter in the previous year, the business posted $0.26 EPS. Omnicell’s revenue was up 14.9% compared to the same quarter last year. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. As a group, equities analysts expect that Omnicell will post 1.31 EPS for the current fiscal year.

Insider Activity at Omnicell

In other news, EVP Corey J. Manley sold 5,025 shares of the stock in a transaction on Monday, May 18th. The stock was sold at an average price of $43.22, for a total transaction of $217,180.50. Following the transaction, the executive vice president directly owned 112,783 shares of the company’s stock, valued at $4,874,481.26. This represents a 4.27% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Nnamdi Njoku sold 3,090 shares of the firm’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $43.22, for a total value of $133,549.80. Following the completion of the transaction, the executive vice president owned 154,785 shares in the company, valued at approximately $6,689,807.70. This trade represents a 1.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 2.92% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of OMCL. Wellington Management Group LLP boosted its position in Omnicell by 156.4% in the fourth quarter. Wellington Management Group LLP now owns 2,075,362 shares of the company’s stock worth $94,014,000 after purchasing an additional 1,265,818 shares during the last quarter. Millennium Management LLC purchased a new stake in shares of Omnicell during the 3rd quarter valued at about $25,625,000. First Light Asset Management LLC purchased a new stake in shares of Omnicell during the 1st quarter valued at about $16,351,000. Boston Partners bought a new position in shares of Omnicell in the 4th quarter worth approximately $20,805,000. Finally, WCM Investment Management LLC bought a new position in shares of Omnicell in the 1st quarter worth approximately $9,783,000. Institutional investors own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.